TEUCER DIAGNOSTICS, INC.

Medtech · Private

Urinary biomarker diagnostic test for podocyturia to detect early endothelial damage and assess cardiovascular disease risk

Grants
$306K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Podocyturia based assay as a predictive biomarker for systemic vascular diseases$306,101
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2039PERSISTENCE THERAPEUTICS, INC.——
2040EYESCREEN, INC.——
2041KATE ALLYN PROSTHETIC RESEARCH——
2042TEUCER DIAGNOSTICS, INC.——
2043SPIROMATICS, INC.——
2044INTRINSIC POWERS, INC.——
2045LINK MEDICAL LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.